{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Gènes modificateurs : Questions médicales les plus fréquentes",
"headline": "Gènes modificateurs : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Gènes modificateurs : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-30",
"dateModified": "2025-04-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Gènes modificateurs"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Gènes",
"url": "https://questionsmedicales.fr/mesh/D005796",
"about": {
"@type": "MedicalCondition",
"name": "Gènes",
"code": {
"@type": "MedicalCode",
"code": "D005796",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Gènes modificateurs",
"alternateName": "Genes, Modifier",
"code": {
"@type": "MedicalCode",
"code": "D060045",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Harriet Corvol",
"url": "https://questionsmedicales.fr/author/Harriet%20Corvol",
"affiliation": {
"@type": "Organization",
"name": "Sorbonne Université, Inserm U938, Centre de Recherche Saint-Antoine (CRSA), 75012 Paris, France."
}
},
{
"@type": "Person",
"name": "Yuanjian Chen",
"url": "https://questionsmedicales.fr/author/Yuanjian%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America."
}
},
{
"@type": "Person",
"name": "Fuyi Xu",
"url": "https://questionsmedicales.fr/author/Fuyi%20Xu",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN, United States of America."
}
},
{
"@type": "Person",
"name": "Robert W Williams",
"url": "https://questionsmedicales.fr/author/Robert%20W%20Williams",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN, United States of America."
}
},
{
"@type": "Person",
"name": "Syamal K Bhattacharya",
"url": "https://questionsmedicales.fr/author/Syamal%20K%20Bhattacharya",
"affiliation": {
"@type": "Organization",
"name": "Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Black Women and the Preemie Prep for Parents (P3) Program: Exploratory Analysis of a Clinical Trial.",
"datePublished": "2024-08-28",
"url": "https://questionsmedicales.fr/article/39252895",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1101/2024.08.28.24312637"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of a Multidisciplinary Service Line and Program for Transcatheter Device Closure of the Neonatal Ductus Arteriosus.",
"datePublished": "2024-08-28",
"url": "https://questionsmedicales.fr/article/39196349",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00246-024-03629-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Parichay Patient Support Program: Useful Tool for Improving Compliance in Kidney Transplant Recipients.",
"datePublished": "2024-08-28",
"url": "https://questionsmedicales.fr/article/39209670",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.transproceed.2024.08.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "User guide for Social Determinants of Health Survey data in the All of Us Research Program.",
"datePublished": "2024-08-27",
"url": "https://questionsmedicales.fr/article/39190874",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/jamia/ocae214"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Systematic Review of the Completion of Cardiac Rehabilitation Programs for Adults Aged 18-50 Years.",
"datePublished": "2024-08-26",
"url": "https://questionsmedicales.fr/article/39185913",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/HCR.0000000000000881"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Gènes modificateurs",
"item": "https://questionsmedicales.fr/mesh/D060045"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Gènes modificateurs - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Gènes modificateurs",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Gènes modificateurs",
"description": "Comment identifier les gènes modificateurs ?\nQuels tests sont utilisés pour les gènes modificateurs ?\nLes gènes modificateurs sont-ils testés en routine ?\nPeut-on détecter les gènes modificateurs par imagerie ?\nQuel rôle jouent les gènes modificateurs dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Immunization+Programs&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Gènes modificateurs",
"description": "Les gènes modificateurs affectent-ils les symptômes ?\nQuels symptômes sont liés aux gènes modificateurs ?\nLes gènes modificateurs causent-ils des symptômes ?\nPeut-on prédire les symptômes avec des gènes modificateurs ?\nLes gènes modificateurs sont-ils liés à des symptômes spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Immunization+Programs&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Gènes modificateurs",
"description": "Peut-on prévenir les effets des gènes modificateurs ?\nY a-t-il des mesures préventives spécifiques ?\nLes gènes modificateurs nécessitent-ils une prévention ciblée ?\nComment la recherche aide-t-elle à la prévention ?\nLes gènes modificateurs influencent-ils le mode de vie préventif ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Immunization+Programs&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Gènes modificateurs",
"description": "Les traitements ciblent-ils les gènes modificateurs ?\nComment les gènes modificateurs influencent-ils le traitement ?\nY a-t-il des traitements spécifiques pour les gènes modificateurs ?\nLes gènes modificateurs affectent-ils l'efficacité des médicaments ?\nPeut-on modifier les gènes modificateurs par traitement ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Immunization+Programs&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Gènes modificateurs",
"description": "Quels types de complications sont liés aux gènes modificateurs ?\nLes gènes modificateurs augmentent-ils les complications ?\nComment gérer les complications liées aux gènes modificateurs ?\nLes complications sont-elles prévisibles avec des gènes modificateurs ?\nLes gènes modificateurs sont-ils impliqués dans des complications spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Immunization+Programs&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Gènes modificateurs",
"description": "Quels sont les facteurs de risque liés aux gènes modificateurs ?\nLes gènes modificateurs augmentent-ils le risque de maladies ?\nComment évaluer les facteurs de risque génétiques ?\nLes facteurs environnementaux influencent-ils les gènes modificateurs ?\nPeut-on modifier les facteurs de risque liés aux gènes modificateurs ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Immunization+Programs&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les gènes modificateurs ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse génétique et les études d'association sont utilisées pour identifier ces gènes."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les gènes modificateurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de séquençage et les SNP (polymorphismes nucléotidiques) sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs sont-ils testés en routine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, leur test n'est pas systématique et dépend des maladies spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les gènes modificateurs par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'imagerie ne permet pas de détecter les gènes modificateurs, seuls les tests génétiques le peuvent."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent les gènes modificateurs dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils aident à comprendre la variabilité des maladies et à affiner le diagnostic."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs affectent-ils les symptômes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent influencer la gravité et la présentation des symptômes d'une maladie."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux gènes modificateurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon la maladie, mais incluent souvent des manifestations cliniques variées."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs causent-ils des symptômes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils modifient l'expression des symptômes causés par d'autres gènes."
}
},
{
"@type": "Question",
"name": "Peut-on prédire les symptômes avec des gènes modificateurs ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Partiellement, car ils peuvent influencer la sévérité mais pas toujours la présence des symptômes."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs sont-ils liés à des symptômes spécifiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes modificateurs sont associés à des symptômes spécifiques dans certaines maladies."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les effets des gènes modificateurs ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est complexe, mais une surveillance et un dépistage précoce peuvent aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des conseils génétiques et des tests peuvent être proposés aux familles à risque."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs nécessitent-ils une prévention ciblée ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la prévention peut être ciblée en fonction des gènes modificateurs identifiés."
}
},
{
"@type": "Question",
"name": "Comment la recherche aide-t-elle à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "La recherche sur les gènes modificateurs aide à identifier des stratégies préventives efficaces."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs influencent-ils le mode de vie préventif ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent guider les recommandations de mode de vie pour réduire les risques."
}
},
{
"@type": "Question",
"name": "Les traitements ciblent-ils les gènes modificateurs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains traitements peuvent être adaptés en fonction des gènes modificateurs identifiés."
}
},
{
"@type": "Question",
"name": "Comment les gènes modificateurs influencent-ils le traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent déterminer la réponse au traitement et la nécessité d'une approche personnalisée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour les gènes modificateurs ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il n'existe pas de traitements spécifiques, mais des approches personnalisées peuvent être envisagées."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs affectent-ils l'efficacité des médicaments ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent influencer l'efficacité et les effets secondaires des médicaments."
}
},
{
"@type": "Question",
"name": "Peut-on modifier les gènes modificateurs par traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur la thérapie génique, mais ce n'est pas encore courant."
}
},
{
"@type": "Question",
"name": "Quels types de complications sont liés aux gènes modificateurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications varient selon la maladie, incluant des formes plus graves ou résistantes."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs augmentent-ils les complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent augmenter le risque de complications dans certaines conditions génétiques."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux gènes modificateurs ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une gestion proactive et personnalisée est essentielle pour minimiser les complications."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles avec des gènes modificateurs ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Partiellement, car certains gènes modificateurs peuvent indiquer un risque accru de complications."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs sont-ils impliqués dans des complications spécifiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes modificateurs sont associés à des complications spécifiques dans certaines maladies."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque liés aux gènes modificateurs ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent des antécédents familiaux et des variations génétiques spécifiques."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs augmentent-ils le risque de maladies ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent augmenter le risque de développer certaines maladies génétiques."
}
},
{
"@type": "Question",
"name": "Comment évaluer les facteurs de risque génétiques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par des tests génétiques et des conseils génétiques appropriés."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils les gènes modificateurs ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'environnement peut interagir avec les gènes modificateurs et influencer le risque."
}
},
{
"@type": "Question",
"name": "Peut-on modifier les facteurs de risque liés aux gènes modificateurs ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines modifications du mode de vie peuvent réduire le risque, mais pas tous les facteurs sont modifiables."
}
}
]
}
]
}
The smartphone Preemie Prep for Parents (P3) program was developed to address the gap in prenatal education of preterm birth in high-risk pregnancies. Despite a higher incidence of preterm birth, Blac...
Pregnant women with medical conditions that predisposed them to preterm birth were randomized to receive the P3 program or links to American College of Obstetricians and Gynecologists webpages (contro...
Of the 26 Black non-Hispanic women enrolled, the P3 group (n=14) had higher knowledge scores than the control group (n=12), 67.5% correct vs. 43.6% (difference 24.0; 95% CI, 7.4 to 40.6), without expe...
The P3 program appears to be an effective method of providing preterm birth education to Black pregnant women....
Outline a quality initiative establishing an institutional service line for neonatal transcatheter device closure of the patent ductus arteriosus (TDC-PDA). A retrospective descriptive observational s...
Medication nonadherence (MNA) in organ transplant recipients is associated with increased risk of rejection, allograft loss, patient death, and higher healthcare costs. Various approaches have been us...
A total of 3352 patients from all over the country were prospectively enrolled in the Parichay PSP between January 2021 and April 2023. Baseline demographic details were recorded. A monthly call was m...
The Parichay PSP had enrolled a total of 1371 kidney transplant patients in 2021, 1620 in 2022, and 361 in 2023 (January-April) from different parts of India (North, 25%; East, 35%; South, 26%; West, ...
This analysis demonstrates that participation in a PSP can be a useful tool for monitoring compliance and tacrolimus therapeutic drug monitoring in kidney transplant recipients....
Integration of social determinants of health into health outcomes research will allow researchers to study health inequities. The All of Us Research Program has the potential to be a rich source of so...
This user guide targets registered users of the All of Us Research Hub Researcher Workbench, a cloud-based platform that supports analysis of All of Us data, who are currently conducting or planning t...
We introduce 14 constructs evaluated as part of the Social Determinants of Health Survey and summarize construct operationalization. We offer 30 literature-informed recommendations for scoring partici...
To perform a systematic review of completion rates of cardiac rehabilitation (CR) in adults aged 18 to 50 yr and describe how core components were reported, measured, and tailored to those under 50 yr...
Database search of MEDLINE, Embase, Emcare, PsycINFO, CINAHL, Scopus, and the Cochrane Library based on keywords, including articles from January 1, 1990. The last search was performed on April 21, 20...
Out of the articles screened (n = 24,517), 33 reports across 31 independent studies were considered eligible (n = 1958 patients aged ≤50 yr). Cardiac rehabilitation completion rates ranged from 64% to...
We report the case of a 37-year-old male athlete, who developed during exercise atrial and ventricular arrhythmias. No structural heart disease....
Invasive programmed ventricular stimulation induced ventricular fibrillation. A heterozygous mutation in the CASQ2 gene (c.775G>T, p.E259X) was found....
The findings in our patient may suggest some increased ventricular excitability using programmed ventricular stimulation in CASQ2 polymorphic ventricular tachycardia patients....
Hormone-based reproductive management programs can be beneficial to improve dairy cow's reproductive performance. This study aimed to compare the economic impact of reproductive management programs us...
To assess the impact of an Outpatient Word Catheter Program (OWCP) on outcomes in women presenting with Bartholin cysts or abscesses (BC/BAs). ....
This retrospective cohort study reviewed 408 women presenting with BC/BAs to our tertiary unit from 2017-2022. Analysis of medical records, with subgroup analysis of pregnant patients, and comparative...
Pre-intervention, 65% (n = 34) of procedures were completed in theater, but after the introduction of OWCP, 61% (n = 213) of cases were treated in the day ward (χ...
After OWCP introduction, there were significant decreases in inpatient admissions, surgical procedures in theater, general anesthetic exposure, and duration of admission. Financial impact analysis rev...
Gun violence is a public health crisis, but nurses report receiving little education related to gun violence prevention (GVP)....
This study aimed to describe undergraduate nursing faculty teaching behaviors and perceptions related to GVP and explore factors associated with teaching it....
A cross-sectional survey design was used....
Less than one-third of faculty taught GVP. Knowledge, confidence, and beliefs were significantly associated with teaching GVP. Most were favorable to include GVP in curricula and agreed assessing for ...
Faculty agree that GVP should be taught, but most do not teach it in undergraduate nursing programs. Faculty development programs focused on GVP and support from national nursing organizations may dec...
To investigate the influence of transarterial embolization (TAE) on programmed cell death-ligand 1(PD-L1) expression and CD8...
An orthotopic HCC model was established in twenty SD rats treated with TAE (lipiodol, n = 10) or sham (normal saline, n = 10) using homologous N1S1 hepatoma cells. Rats were euthanized 1 week after em...
The CD4/CD8 ratio and PD-1...
Immune cells are distributed unevenly in the tumours after TAE. The intrinsic induction state of the tumour after embolization may be insufficient to elicit a maximal response to PD-1/PD-L1 inhibitors...